In the early nineteen eighties, seven young Americans developed severe and acute symptoms of Parkinson’s disease shortly after injecting themselves with a new synthetic heroine. This incident has dramatically changed the way we think about the cause and treatment of Parkinson’s disease. Now, thirty years later, Jorik Nonnekes and Bas Bloem of Radboud university medical center have obtained the original video images of these patients. Based on this unique footage, they have made two interesting new observations that had not been noted in the original descriptions. They describe their observations in an article in the 15 March edition of The Lancet Neurology.In 1982, a young man presented at the emergency department of the Santa Clara Valley Medical Center in California with acute symptoms of advanced Parkinson’s disease. The treating physicians were puzzled. Neurologist Bill Langston was intrigued by this patient and shortly thereafter located six more similar cases. He discovered that they had all used MPTP, a new synthetic drug similar to heroin. Their symptoms disappeared after administering levodopa, a drug also used for Parkinson’s disease.
In the nineteen eighties of the last century, Langston published a series of seminal articles on this MPTP-induced parkinsonism in high-impact journals such as Science. The discovery of MPTP-induced parkinsonism has had an enormous impact on our entire understanding of Parkinson’s disease. Langston collected video footage of these patients with MPTP-induced parkinsonism, but the videos were never published. Now, thirty years later, Bas Bloem and Jorik Nonnekes of Radboud university medical center publish these ‘vintage’ video images, together with Bill Langston. Careful review of these videos, in light of today’s knowledge, revealed two new observations that had remained unnoticed in the eighties.
Freezing of gait
One observation concerns freezing of gait, a disabling symptom that many Parkinson’s patients experience in advanced stages of the disease. During freezing of gait, patients have the feeling that their feet suddenly become glued to the floor. Jorik Nonnekes: “Surprisingly, freezing of gait was just not seen in the MPTP-patients, although you would expect this given their marked disease severity. However, we did see the classical picture of freezing of gait in one patient who had been treated with levodopa for several years. This may indicate that long-term use of levodopa plays a role in causing freezing.”
Large differences between patients
The researchers also discovered two subtypes of MPTP-induced parkinsonism in the footage. There is a relative mild subtype that is accompanied by pronounced tremors, and a more severe variant characterized mainly by stiffness and extreme slowness of movements. These subtypes are also seen in Parkinson’s patients. Bas Bloem, professor of Neurology at Radboud university medical center: “We still don’t understand properly why people with Parkinson’s disease differ so much from one another. It was a revelation for me to see such huge differences between people who had the exact same cause (MPTP) for their parkinsonism. The ability of healthy areas of the brain to compensate for MPTP damage might explain the presence of these subtypes. This ability to compensate varies considerably between different patients.’
Bas Bloem: “The discovery of these seven patients in the early eighties was nothing less than a complete revolution in the world of Parkinson’s. Now, for the first time, we are showing the unique images of these patients to the medical world. They are really special from a historical perspective. And it is an extra bonus that review of these original images helped us to obtain new insights that can further support us in developing better treatments.”
How MPTP works
Parkinson’s disease is due to progressive loss of cells in the substantia nigra. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is an organic compound that is highly toxic for nerve cells in the substantia nigra. This brain area produces the substance dopamine that is vital for controlling movement. The toxic effect of MPTP results in an acute depletion of dopamine, which then produces symptoms that are very similar to those of Parkinson’s disease, such as shaking (tremor) and slow movements.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more